Cargando…

Plasma mutant α-galactosidase A protein and globotriaosylsphingosine level in Fabry disease

Fabry disease is an X-linked genetic disorder characterized by deficient activity of α-galactosidase A (GLA) and accumulation of glycolipids, and various GLA gene mutations lead to a wide range of clinical phenotypes from the classic form to the later-onset one. To investigate the biochemical hetero...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsukimura, Takahiro, Nakano, Sachie, Togawa, Tadayasu, Tanaka, Toshie, Saito, Seiji, Ohno, Kazuki, Shibasaki, Futoshi, Sakuraba, Hitoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5121323/ https://www.ncbi.nlm.nih.gov/pubmed/27896103 http://dx.doi.org/10.1016/j.ymgmr.2014.07.005

Ejemplares similares

Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease
por: Sueoka, Hideaki, et al.
Publicado: (2015)

Does administration of hydroxychloroquine/amiodarone accelerate accumulation of globotriaosylceramide and globotriaosylsphingosine in Fabry mice?
por: Tsukimura, Takahiro, et al.
Publicado: (2021)

Development of a Highly Sensitive Immuno-PCR Assay for the Measurement of α-Galactosidase A Protein Levels in Serum and Plasma
por: Nakano, Sachie, et al.
Publicado: (2013)

Fabry disease in a Japanese population-molecular and biochemical characteristics
por: Sakuraba, Hitoshi, et al.
Publicado: (2018)

Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy
por: Nakano, Sachie, et al.
Publicado: (2015)

Clinical and biochemical investigation of male patients exhibiting membranous cytoplasmic bodies in biopsied kidney tissues; a pitfall in diagnosis of Fabry disease
por: Sakuraba, Hitoshi, et al.
Publicado: (2015)

Nano-LC-MS/MS for Quantification of Lyso-Gb3 and Its Analogues Reveals a Useful Biomarker for Fabry Disease
por: Sueoka, Hideaki, et al.
Publicado: (2015)

Comparative urinary globotriaosylceramide analysis by thin-layer chromatography-immunostaining and liquid chromatography-tandem mass spectrometry in patients with Fabry disease
por: Shiga, Tomoko, et al.
Publicado: (2021)

Monitoring of anti-drug antibodies and disease-specific biomarkers in three patients from a Japanese Fabry family treated with enzyme replacement therapy
por: Kubota, Takao, et al.
Publicado: (2022)

Anti-drug antibody formation in Japanese Fabry patients following enzyme replacement therapy
por: Tsukimura, Takahiro, et al.
Publicado: (2020)

Cell Transplantation Combined with Recombinant Collagen Peptides for the Treatment of Fabry Disease
por: Kami, Daisuke, et al.
Publicado: (2020)

Genetically Modified Cell Transplantation Through Macroencapsulated Spheroids with Scaffolds to Treat Fabry Disease
por: Kami, Daisuke, et al.
Publicado: (2021)

Globotriaosylsphingosine Accumulation and Not Alpha-Galactosidase-A Deficiency Causes Endothelial Dysfunction in Fabry Disease
por: Namdar, Mehdi, et al.
Publicado: (2012)

Screening of Fabry disease in patients with chronic kidney disease in Japan
por: Nagata, Akiko, et al.
Publicado: (2021)

Erratum to: Screening of Fabry disease in patients with chronic kidney disease in Japan
por: Nagata, Akiko, et al.
Publicado: (2021)

Plasma Globotriaosylsphingosine and α-Galactosidase A Activity as a Combined Screening Biomarker for Fabry Disease in a Large Japanese Cohort
por: Maruyama, Hiroki, et al.
Publicado: (2021)

Comparative Study of Structural Changes Caused by Different Substitutions at the Same Residue on α-Galactosidase A
por: Saito, Seiji, et al.
Publicado: (2013)

Surface plasmon resonance analysis of complex formation of therapeutic recombinant lysosomal enzymes with domain 9 of human cation-independent mannose 6-phosphate receptor
por: Kanzaki, Minori, et al.
Publicado: (2020)

Effectiveness of immunosuppressive therapy for nephrotic syndrome in a patient with late-onset Fabry disease: a case report and literature review
por: Fujisawa, Hironobu, et al.
Publicado: (2019)

Clinical significance of plasma globotriaosylsphingosine levels in Chinese patients with Fabry disease
por: Ouyang, Yan, et al.
Publicado: (2018)

Monitoring globotriaosylsphingosine in a Korean male patient with Fabry disease
por: Jang, Heejoon, et al.
Publicado: (2019)

Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb(3)) in Fabry Transgenic Mice and in the Plasma of Fabry Patients
por: Young-Gqamana, Brandy, et al.
Publicado: (2013)

In Vivo Delivery of Therapeutic Molecules by Transplantation of Genome-Edited Induced Pluripotent Stem Cells
por: Nakajima, Ittetsu, et al.
Publicado: (2023)

Distinctive accumulation of globotriaosylceramide and globotriaosylsphingosine in a mouse model of classic Fabry disease
por: Taguchi, Atsumi, et al.
Publicado: (2023)

Pulmonary involvement in Fabry disease: effect of plasma globotriaosylsphingosine and time to initiation of enzyme replacement therapy
por: Franzen, Daniel, et al.
Publicado: (2018)

A new mutation found in newborn screening for Fabry disease evaluated by plasma globotriaosylsphingosine levels
por: Chinen, Yasutsugu, et al.
Publicado: (2017)

Structural Basis of Mucopolysaccharidosis Type II and Construction of a Database of Mutant Iduronate 2-Sulfatases
por: Saito, Seiji, et al.
Publicado: (2016)

FcRγ-dependent immune activation initiates astrogliosis during the asymptomatic phase of Sandhoff disease model mice
por: Ogawa, Yasuhiro, et al.
Publicado: (2017)

Human α-Galactosidase A Mutants: Priceless Tools to Develop Novel Therapies for Fabry Disease
por: Modrego, Andrea, et al.
Publicado: (2021)

Lyso-GM2 Ganglioside: A Possible Biomarker of Tay-Sachs Disease and Sandhoff Disease
por: Kodama, Takashi, et al.
Publicado: (2011)

Optimizing human α-galactosidase for treatment of Fabry disease
por: Hallows, William C., et al.
Publicado: (2023)

Analysis of Lyso-Globotriaosylsphingosine in Dried Blood Spots
por: Johnson, Britt, et al.
Publicado: (2013)

Adipocytes participate in storage in α-galactosidase deficiency (Fabry disease)
por: Hůlková, Helena, et al.
Publicado: (2010)

A Pharmacogenetic Approach to Identify Mutant Forms of α-Galactosidase A that Respond to a Pharmacological Chaperone for Fabry Disease
por: Wu, Xiaoyang, et al.
Publicado: (2011)

Receptor-Mediated Endocytosis of α-Galactosidase A in Human Podocytes in Fabry Disease
por: Prabakaran, Thaneas, et al.
Publicado: (2011)

A Novel α-Galactosidase A Splicing Mutation Predisposes to Fabry Disease
por: Li, Ping, et al.
Publicado: (2019)

Rats deficient in α-galactosidase A develop ocular manifestations of Fabry disease
por: Miller, James J., et al.
Publicado: (2019)

Impaired Neural Differentiation of Induced Pluripotent Stem Cells Generated from a Mouse Model of Sandhoff Disease
por: Ogawa, Yasuhiro, et al.
Publicado: (2013)

Mass Spectrometry Analysis of Globotriaosylsphingosine and Its Analogues in Dried Blood Spots
por: Boutin, Michel, et al.
Publicado: (2023)

A Novel Frameshift Mutation of Galactosidase-alpha in Fabry Disease Restricted to Dermatologic Manifestations
por: Kim, Dae Hun, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_dv4uoir1e7hlt3e57k923tbksc